Moleculin Biotech, Inc. Depreciation
Moleculin Biotech, Inc. (MBRX) reported Depreciation of $100.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-03-18
- Moleculin Biotech, Inc. depreciation for fiscal 2025 was $100.00K.
| Period end | Depreciation 9 month | Depreciation 12 month |
|---|---|---|
| 2025-12-31 | $100.00K 10-K · filed 2026-03-18 | |
| 2018-09-30 | $30.00K 10-Q · filed 2018-11-13 | |
| 2017-09-30 | $10.00K 10-Q · filed 2018-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |